Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: Evidence of stage migration from the ACCENT database

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3656-3663

  Shi, Qian ^a   Andre, Thierry ^b   Grothey, Axel ^a   Yothers, Greg ^c   Hamilton, Stanley R ^e   Bot, Brian M ^a,f   Haller, Daniel G ^d   Van Cutsem, Eric ^h   Twelves, Chris ⁱ   Benedetti, Jacqueline K ^g   O'Connell, Michael J ^c   Sargent, Daniel J ^a  

^a North Central Cancer Treatment Group Rochester   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c NSABP Foundation Inc   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f SAGE BIONETWORKS   (United States)

^g SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONFERENCE PAPER; FEMALE; HUMAN; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; TIME FROM RECURRENCE TO DEATH; TIME TO RECURRENCE; COLONIC NEOPLASMS; COMPARATIVE STUDY; LYMPH NODE; MIDDLE AGED; MORTALITY; PATHOLOGY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891589369     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.4344     Document Type: Conference Paper

References (25)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Edwards BK, Ward E, Kohler BA, et al: Report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573, 2010
3. Desch CE, Benson AB 3rd, Somerfield MR, et al: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512-8519, 2005
4. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial-Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate-Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992
6. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
7. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
8. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23: 8671-8678, 2005
9. Gray R, Barnwell J, McConkey C, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
10. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009
11. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
12. Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006
13. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
14. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
15. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
16. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
17. Nelson H, Petrelli N, Carlin A, et al: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93:583-596, 2001
18. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial-QUASAR Collaborative Group. Lancet 355:1588-1596, 2000
19. André T, Quinaux E, Louvet C, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 25: 3732-3738, 2007
20. Fielding LP, Arsenault PA, Chapuis PH, et al: Clinicopathological staging for colorectal cancer: An International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6:325-344, 1991
21. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604-1608, 1985
22. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683, 2009
23. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 77:1241-1246, 1990
24. de Gramont A, Hubbard J, Shi Q, et al: Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28:460-465, 2010
25. Grothey A, de Gramont A, Sargent DJ: Disease-free survival in colon cancer: Still relevant after all these years! J Clin Oncol 31:1609-1610, 2013